Davion Pays $13.5M for Profitable US Home Healthcare Business
DAVI is trading near its 52-week low of $2.78 (12% above the low) on elevated volume (2.7× avg).
Summary
Davion agreed to buy a profitable US home healthcare business for $13.5 million, with total consideration comprising $8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. That is a meaningful outlay for a company of this size, and it pushes the group beyond wound-care IP into direct care delivery. It follows the October 26 close of the WoundSkan and Spektra IP purchase, a $25 million deal structured as $2.5 million cash plus stock, so management is stringing together deals quickly. The key detail is the target's profitability: for FY 2025, HSH reported gross receipts of about $11.6 million and ordinary business income of about $1.9 million.
At the time of this announcement, DAVI was trading at $3.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $82.2M. The 52-week trading range was $2.78 to $12.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.